Try our Advanced Search for more refined results
Life Sciences - February, 2014
277 articles
- Merck Says DOJ Has Ended Its Multicountry FCPA Probe
- High Court Must Fix Claim Construction Rule Now, Teva Says
- Actelion Settles Row Over Giving Drugs To Generics Makers
- FDA Updates Guidance On Avoiding Off-Label Promotion
- Pa. High Court's Design Ruling Revives Fen-Phen Suit
- Female Powerbrokers Q&A: Holland & Knight's Anita Mosner
- Female Powerbrokers Q&A: Covington's Christine Haskett
- FCA Suits Over Poor Drug Quality Are Down But Not Out
- Amarin Sues FDA Over Vascepa Market Exclusivity Denial
- Handful Of Banner Deals Define M&A In February
- Ex-SAC Manager Martoma Wants Conviction Thrown Out
- Takeda Accuses Watson Of Stepping On Gout Drug Patents
- Boiron Ducks Class Cert. In Suit Over Flu Remedy Label
- Amgen Anniversary Brings New Battle To Supreme Court
- Judge Reverses Precedex Patent Invalidation Following Deal
- Santaris Can't Skirt Infringement Claim In Isis Patent Row
- Health Care Orgs Call On FDA To Stop Painkiller Launch
- DOJ Skittish About Supreme Court Review Of FCA Pleading
- Omnicare Pays $4.2M To End FCA Suit Over Amgen Kickbacks
- Bulk Of $4M Fen-Phen Referral Fee Award Upheld On Appeal
- China Anti-Bribery Rules Raise Questions For Life Sciences
- FDA, EMA Back Safety Of Diabetes Drugs Targeted In MDL
- FRCP Discovery Amendments Prove Highly Controversial
- Sanofi Sues Watson, Glenmark Over Planned Multaq Generics
- W.Va. Plavix Ad Claims Remanded To State Court
- Meda Sues Perrigo, Impax Over Generic Nasal Spray
- Female Powerbrokers Q&A: Buchalter's Shawn Christianson
- Female Powerbrokers Q&A: Robins Kaplan's Hollis Salzman
- Bayer Snaps Up Chinese Over-The-Counter Drug Co.
- Ameritox Loses Sanctions Bid In Millennium Antitrust Suit
- Fed. Circ. Won't Rehear IP Suit Over Hanmi's Nexium Generic
- Stiefel Urges 11th Circ. To Reverse $1.5M Stock Sale Ruling
- Infusion Pump Co. Tells Jury Rival Had Plan To Infringe IP
- FDA Spied On Staff Without Considering Legal Risks: Report
- JPML Sends 12 Solodyn Antitrust Suits To Mass.
- Health Fraud Crackdown Nets $4.3B In 2013, Feds Say
- Celera Shareholders Win Class Cert.
- FDA Won't Change Medical Device Notification Rules
- GSK Can't Shake Calif. County's Avandia False Ad Claims
- Female Powerbrokers Q&A: Sedgwick's Stephanie Sheridan
- Female Powerbrokers Q&A: Pryor Cashman's Colleen Caden
- High Court Should Reverse 4th Circ.'s Flawed FCA Ruling
- Latham Snags Ex-Ropes & Gray White Collar Pro
- Brownstein Grows IP Team With 5 New Attys In Denver
- Armstrong, Supplement Co. Cycle Past False Marketing Suit
- J&J, Ethicon Sued Over Surgical Stapler Misfire
- Firms Kick Off Benicar Diarrhea Suits Against Daiichi
- LA Hospital Won't Bend In Ongoing Fight Over Knee Patents
- Shire Unit Settles Genzyme False Advertising Suit
- FDA Rips Research Co. Over Unapproved Electromagnet Trials
- Grand Jury Gets Last Word On Criminal Charges: High Court
- Salix Wins Jury Verdict In Breach Suit Over Napo Drug
- FDA Announces Recalls Of Trachea Tube, Catheter Devices
- The Unstoppable Trailblazer: Judge Shira Scheindlin
- Arent Fox Adds Ex-Novak Druce IP Pro In San Francisco
- FDA Blasts Another Indian Drug Firm Over Suspect Records
- Female Powerbrokers Q&A: Dentons' Kara Baysinger
- Female Powerbrokers Q&A: Winston & Strawn's Joan Fife
- The Continuing Saga Of Mayo V. Prometheus
- Deals Rumor Mill: BlackBerry, SoftBank, Chevron
- 9th Circ. Nixes Daw's Prosthetic Knee Antitrust Suit
- Total, Endo Units Hit With Vaginal Mesh Suit In Texas
- $6M Qui Tam Award Is Income, Not Capital Gain: Tax Court
- Zoloft False Ad Suit Time-Barred, Judge Finds
- Eli Lilly To Buy German Animal Health Business Lohmann
- J&J Hid Topamax Birth Defect Risks, Philly Jury Hears
- Rep. Urges Obama To Back Repeal Of ACA Medical Device Tax
- Fed. Circ. Upholds GSK Win Over Avodart Patent
- Female Powerbrokers Q&A: Bingham's Debra Fischer
- Female Powerbrokers Q&A: Nossaman's Nancy Smith
- Cinven Pays $915M For Clinical Research Co. Medpace
- Forest Investor Says $25B Actavis Offer Is Insufficient
- Par Pharma Loses Bid To Keep Appetite Drug Patent
- 5th Circ. Affirms Brand, Generic Wins In Reglan Suits
- FDA Chief Predicts Long Road For India Quality Reforms
- Ex-Texas Atty's Bid To Reverse 20-Year Sentence Rejected
- Miami New Times Cleared In Doping Clinic Privacy Suit
- Novartis Can't Shake $1.3M Zometa Verdict
- FDA Plans Overhaul Of Over-The-Counter Drug System
- GSK Cleared To Appeal RICO Questions In Avandia Suits
- CORRECTED: Endo Inks $193M Deal Over Off-Label Lidoderm Marketing
- Glaser Weil Lures McKool Atty Who Saved Ultramercial IP
- Lewis Brisbois Grabs Nelson Levine Pros For Pa. Expansion
- Female Powerbrokers Q&A: Ropes & Gray's Jane Goldstein
- Female Powerbrokers Q&A: Snell & Wilmer's Barb Dawson
- Law360 Life Sciences Editorial Advisory Board
- Pa. Appeals Court Won't Rehear Fixodent Evidence Dispute
- FDA Reverses Course On Exclusivity For New Drug Combos
- 9th Circ. Refuses To Revive Novartis Jaw Injury Suit
- Rotech Appeals Baker & McKenzie's Fee Award In Ch. 11 Case
- J&J Mesh Suits Belong In Federal Court, 10th Circ. Told
- Paul Hastings Nabs Pfizer's Top Compliance Officer
- Cipro Buyers Say Cos. Are Denying 'Stark Reality' Of Actavis
- Sports Clinic Owner Says MLB Ruined His Reputation
- Endo Puts Aside $520M For Vaginal Mesh Litigation
- Fed. Circ. Nixes Win For Takeda In Generic Prevacid Case
- J&J Blood Thinner Xarelto Caused Bleeding, Suit Says
- Deals Rumor Mill: Nokia, Merck, J. Jill
- Female Powerbrokers Q&A: Choate's Melissa Tearney
- Female Powerbrokers Q&A: Littler's Lee Schreter
- 9th Circ. Ruling Helps Nonparties Fight Abusive Discovery
- FDA Import Reforms To Fuel Fights Over Drugmaking Slip-Ups
- FTC Bags $2M False Ad Win Against Diabetes Supplement Co.
- Patent Trolls May Soon Threaten Drug Industry, Study Says
- USPTO Can't Be Blamed For Patent On 'Fraud' Stem Cells
- FDA Updates Guidance On Lab Data For New Drugs
- NY AG Takes Up Pay-For-Delay Mantle With Teva Deal
- CMS Urged To Abandon Medicare Part D Reform Proposal
- Reckitt, Ex-Exec Strike Deal Over 'Phony' $6M Severance
- $134M In Projected Colo. Marijuana Taxes Busts Estimates
- Clinical Trial Regulation Seeks Uniformity Across EU
- Hunton Atty's Alleged Stock Tip Sparks Criminal Probe
- MLB Drops Suit Against Drug Clinic That Supplied A-Rod
- Device Co. EndoGastric To Pay $5M In FCA Kickback Suit
- New Philly Mass Tort Program Created For Pelvic Mesh Suits
- Female Powerbrokers Q&A: Steptoe's Mimi Addy
- Female Powerbrokers Q&A: Ballard Spahr's Mary Mullany
- The Captain Of The Mother Court: Judge Loretta Preska
- Pfizer, GSK To Have Imported Drugs Fast-Tracked By FDA
- New Trial Denied, $1.9M Of Damages Added In Suture IP Row
- Shasta Wants Discovery To Proceed In Glucose Strip IP Case
- JPML Centralizes Lipitor Diabetes Suits In SC
- FDA Vows To Collaborate More With Indian Drug Regulators
- Fed. Circ. Won't Block Ossur Prosthetic Production In IP Row
- Stryker Pays $172M For German Surgical Device Co.
- France's Biosimilar Law May Set Trend Inside The EU
- Inter Partes Review: A Look At The Companies Under Attack
- Merck Sues Xellia Over Plan For Generic Anti-Fungal Drug
- J&J Wins 1st Vaginal Mesh Bellwether Trial
- BioChemics, D&O Insurer Battle Over SEC Subpoena Claim
- FDA Eyes Overhaul Of Risk Disclosure In Pharma Ads
- Female Powerbrokers Q&A: Kaye Scholer's Lori Leskin
- Female Powerbrokers Q&A: Hirschler's Courtney Paulk
- AdvaMed Plans Lobbying On Device Tax, Medicare Payments
- FDA Warns Baxter Over Infusion Pump Quality Controls
- Deals Rumor Mill: Tyson Foods, Peugeot, Starwood
- Latham-Led Actavis Pays $25B For Icahn-Backed Forest Labs
- Pharmacies Want Class Cert. In Pfizer Pay-For-Delay Case
- Med Cable Color Trademarks Can Be Restricted, TTAB Says
- FDA Again Rejects J&J, Bayer Blood Thinner Expansion
- Keryx, CEO Dodge Investor Class Action Over Cancer Drug
- J&J's Discovery Mishaps Barred From Vaginal Mesh Trial
- Medisca Recalls L-Citrulline Lots Amid FDA Warning
- FDA Outlines Feedback Process For Medical Device Approvals
- GSK Announcement May Change Industry Speaker Programs
- Injunction Likely In Case Over Diabetes Pill Ads, Judge Says
- Female Powerbrokers Q&A: Hughes Hubbard's Bassey
- Female Powerbrokers Q&A: Mitchell Silberberg's Coyoca
- P&G Dodges Denture Adhesive Claims In Pa. Court
- 6 Tips For Creating Effective Trial Graphics
- Boehringer Faces 2,000-Plus Pradaxa Injury Suits
- EU Lifts Duties On Chinese Pharma Chemical Imports
- Thermo Fisher Deal Shows Waivers, Timing Cut Antitrust Woes
- Diet Supplement Maker Says Inventor Peddling Its Product
- 10th Circ. Told J&J Pelvic Mesh Suits Belong In State Court
- Medtronic Seeks Reversal Of $393M Award In Valve IP Row
- Female Powerbrokers Q&A: Goodwin Procter's Sharton
- Female Powerbrokers Q&A: Levenfeld's Patti O'Connor
- Calculating Patent Term Adjustment Post-Novartis
- CMS Proposal Leaves Part D Protected Class Unprotected
- Australia Hits Pfizer With Antitrust Suit Over Lipitor
- Hogan Lovells Adds Ex-Kaye Scholer Corporate Partner
- Avanir Shareholders Can't Halt Proxy Vote
- Bill In Fla. Senate Would Legalize Medical Marijuana
- Teijin, Takeda Accuse Lupin Of Infringing Uloric Patent
- IP Challenges In India Being Exaggerated, ITC Told
- 3rd Circ. Mulls Class Cert. In J&J Reagent Antitrust Case
- FDA Hammers Active Ingredient Maker Over 'Severe Hazard'
- DEA Needs Warrants To Get Drug Records, Judge Says
- A Sign Of Long-Term Improvement Of ANDA Review Process
- Deals Rumor Mill: Carlyle, Blackstone, Giant Interactive
- Female Powerbrokers Q&A: Ballard Spahr's Emilie Ninan
- Female Powerbrokers Q&A: Steptoe's Lucinda Low
- Novartis Cancer Unit To Pay $8M To Settle Securities Row
- Biolitec Appeals $63M Sanction, CEO Arrest Order In IP Row
- UMass Takes Patent Dispute With Univ. Of Utah To High Court
- Amgen Hit With FDA Warning Over Drug-Device Combos
- FDA To Review AstraZeneca Diabetes Drug For Heart Risks
- 9th Circ. To Reconsider Its Remand Of Teva Painkiller Suit
- FDA Panel Says Data Don't Show Naproxen Is Safer NSAID
- Fla. Bill Would Let Pharmacies Sue Over Abusive Audits
- La. High Court Reins In State AG Medicaid Fraud Suits
- Mich. Drug Companies Now Less Immune Under Tort Reform
- Sens. Seek To Limit FDA's Health IT Regulatory Oversight
- Surgiview Owes $48M In OrthoTec Licensing Row, Jury Finds
- Seeger Weiss Says Vitamin Shoppe Trademark Suit Falls Short
- Catheter Connections Can't Shake IV-Valve Patent Suit
- Walgreen Misled Buyers Of Homeopathic Remedies, Suit Says
- Mallinckrodt Puts Down $1.3B To Acquire Cadence
- Senior Housing REIT Puts Up $1.1B For Boston Office Towers
- Female Powerbrokers Q&A: Ropes & Gray's Laurel FitzPatrick
- Female Powerbrokers Q&A: Baker Donelson's Donna Fraiche
- Medtronic Tells 10th Circ. Bone Device Suit Is Preempted
- Savient Pharma Unveils Ch. 11 Plan
- GAO, FDA Spar Over Progress On Drug Shortages
- Court Split Over Medical Device Claims Persists
- Roche Looks To Sink $2M Accutane Verdict On Appeal
- PhRMA Moves To Vanquish FTC Rule Targeting Drugmakers
- Pfizer Says 2nd Circ. Can't Review Lipitor FCA Suit
- Expert Testimony Barred In Denture-Adhesive Mass Tort
- Medicare Wrongly Paid $12M For Prisoners' Drugs, HHS Says
- Teva Under Federal Scrutiny Over Potential FCA Breaches
- Female Powerbrokers Q&A: FordHarrison's Tracey Jaensch
- Female Powerbrokers Q&A: McManis' Neda Mansoorian
- Prescription Fraud, Diversion Will Keep Spotlight In 2014
- Industry Groups Urge USTR To Step Up IP Pressure On India
- FDA Updates Disclosure Rules On Medical Device Changes
- J&J Wants Discovery Mishaps Barred From Vaginal Mesh Trial
- 5 Lessons Doctors Can Take From FDA's Big Stem-Cell Win
- How Supreme Court's Medtronic Ruling May Impact Licenses
- Forest Sues Glenmark Over Generic Fibromyalgia Treatment
- FDA Report Finds Big Drop In Drug Shortages
- La. Is Latest State To Demand Causation For Medicaid Fraud
- Myriad, Rival Strike Deal In Cancer-Test Patent Dispute
- Female Powerbrokers Q&A: McAndrews' Nabeela Rasheed
- Female Powerbrokers Q&A: Crowell's Ellen Dwyer
- Merck To Pay $100M To End NuvaRing Blood Clot Suits
- Judge Bars Whistleblower Claims In Liberty Medical Ch. 11
- FDA Details Expectations For Approval Of New Painkillers
- Pfizer Wants Professor's Report Out Of Birth Defect MDL
- Whistleblower Says Celgene Bribed Docs To Sell Cancer Meds
- Tighter Drug-Discount Rules Loom After 340B Report
- Genzyme's Cancer Drug IP Suit Can Proceed, Judge Says
- Fed. Circ. OKs Ruling Barring Generic Lyrica Until 2018
- Ex-SAC Manager Martoma Found Guilty Of Insider Trading
- Novartis Sues Dr. Reddy's Over ANDA For Cancer Drug
- Fla. Justices Mull Sublicense Terms In Blood Device IP Row
- NJ Court Won't Revive Malpractice Suit Over J&J Bias Case
- Female Powerbrokers Q&A: Wendel Rosen's Pamela Mintzer
- Female Powerbrokers Q&A: Hodgson Russ' Yalamanchili
- Litigation Costs Are In Your Control, So Take Control
- Martoma Awaits Verdict As Jury Mulls Defense Testimony
- FCA Perils Mount For Drugmakers As DOJ Gets Personal
- HHS Watchdog Says Rules For 340B Drug Program Unclear
- HHS Announces $90M Partnership For Anti-Bioterrorism Drug
- Abbott Hit With 5 AndroGel Suits In FDA Probe's Wake
- Nutrition Council Backs FTC Dissent On Health Ad Standard
- J&J Punished For Losing Evidence In Vaginal Mesh MDL
- Labeling Beverages And Supplements Post-FDA Guidance
- ArthroCare Investor Sues To Halt $2B Smith & Nephew Merger
- Apotex, Others Ask Fed. Circ. To Nix Allergan Latisse Patents
- Polsinelli Adds New FDA Practice Head In DC
- Myriad Genetics Puts Up $270M For Crescendo Bioscience
- Female Powerbrokers Q&A: Taft's Margaret Lawson
- Female Powerbrokers Q&A: Frankfurt's Barbara Shiers
- Ex-Redskins QB Shakes Prostate Drug False-Ad Suit
- Paul Hastings Helps Arrange $1B Accellent Financing Deal
- Martoma Jury Ends 1st-Day Deliberations With No Verdict
- Genentech, Roche Settle With PDL BioPharma Over Licensing
- BMS Says Genetic Technologies' DNA Tech Is Unpatentable
- 9th Circ. Urged To Reinstate Expert In Novartis Jaw Injury Suit
- Deals Rumor Mill: Liberty, Novartis, Blackstone
- Foley Hoag Lures Ropes & Gray IP Partner For Boston Office
- Drugmakers Tackle Biosimilars Oversight At FTC Forum
- FDA Can Regulate Stem Cell Treatments, DC Circ. Rules
- Negligent Drug Design Claims May Increase In Pa.
- Covidien's $2.5M Wage-And-Hour Settlement Gets Judge's OK
- Female Powerbrokers Q&A: Michelman's Mona Hanna
- Female Powerbrokers Q&A: Baker Donelson's Linda Klein
- Ferring Wins Lysteda Patent Trial Against Watson, Apotex
- Feds Urge Jury To Convict Ex-SAC Trader Martoma
- Biomet To Pay $56M To Settle Hip Replacement MDL
- In-House Counsel Name Client-Friendly Litigators
- GCs Name Best-Of-The-Best Attys
- Victim Of Steroid-Tainted Supplement Wins $4M In Settlements
- Merck To Spend Up To $2.3B In Ablynx Licensing Deal
- Deferred Sanctions Leave Hope For Takeda In Actos MDL
- Akerman Opens Chicago Office With Ulmer & Berne Team
- $3.3M Judgment Against Nature's Upheld In Prolab Row
- Wiley Rein Adds 3 Ex-BakerHostetler IP Attys In DC
- Smith & Nephew Pays $1.7B For Fellow Medical Device Maker
- Montagu Strikes $805M Deal For Rexam's Health Care Biz
- Female Powerbrokers Q&A: Holwell Shuster's Dorit Black
- Female Powerbrokers Q&A: Gibbons' Christine Amalfe
- Valeant Again Boosts Skin Care Biz With $500M PreCision Buy
- Patent Prosecution Lessons From Medtronic V. Edwards
- 1st Circ. Holds FCA Relator's Feet To The Rule 9(b) Fire